Earnings History Data for Cyclo Therapeutics, Inc. (CYTH) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Cyclo Therapeutics, Inc.

Cyclo Therapeutics Inc. is a clinical-stage biotechnology company. It develops cyclodextrin-based products for the treatment of disease. The company's Trappsol(R) Cyclo(TM), an orphan drug designated product primarily in the United States and Europe, is in ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. Cyclo Therapeutics Inc., formerly known as CTD Holdings Inc., is based in ALACHUA, Fla.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume	Top Mover
15-11-2021	AH		CYTH	Cyclo Therapeutics, Inc.	46.16	-0.60	0.00	0.00	Cyclo Therapeutics EPS beats by $0.07, beats on revenue [11/15/2021 5:08 PM]	7.29	0.0 (0.00%)	7.80	0.51 (7.00%)	3.40 - 17.75	1,169,010	40,000	1,287,247
Cyclo Therapeutics EPS beats by $0.07, beats on revenue [11/15/2021 5:08 PM] Cyclo Therapeutics jumps 18% after filing IND application for Trappsol Cyclo in Alzheimer’s Disease [11/16/2021 8:20 AM] Cyclo Therapeutics under pressure on launching stock offering [11/16/2021 4:33 PM] Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results [Nov-15-21 04:20PM] Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo in Phase 2 Study for Treatment of Alzheimers Disease [Nov-16-21 08:05AM] Cyclo Therapeutics Announces Proposed Public Offering of Common Stock [Nov-16-21 04:27PM] Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock [Nov-16-21 08:28PM]